Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Methotrexate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR known ✓ | P00374 | 4/20 | 0.98 |
| ▸ | FPGS | Q05932 | 3/20 | 0.98 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.98 |
| ▸ | TLR4 | O00206 | 1/20 | 0.98 |
| ▸ | MEN1 | O00255 | 1/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.98 |
| ▸ | LMNA | P02545 | 1/20 | 0.98 |
| ▸ | TP53 | P04637 | 1/20 | 0.98 |
| ▸ | TYMS | P04818 | 1/20 | 0.98 |
| ▸ | GLA | P06280 | 1/20 | 0.98 |
| ▸ | POLB | P06746 | 1/20 | 0.98 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.98 |
| ▸ | MAPT | P10636 | 1/20 | 0.98 |
| ▸ | FOLR2 | P14207 | 1/20 | 0.98 |
| ▸ | FOLR1 | P15328 | 1/20 | 0.98 |
| ▸ | HPGD | P15428 | 1/20 | 0.98 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.98 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.98 |
| ▸ | GART | P22102 | 1/20 | 0.98 |
| ▸ | APEX1 | P27695 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methotrexate SCHEMBL11175892 | 1.00 | DHFR (0.98) | DHFRFPGSKDM4ETLR4MEN1 | |
| Methotrexate SCHEMBL4136 | 1.00 | DHFR (0.98) | DHFRFPGSKDM4ETLR4MEN1 | |
| Methotrexate SCHEMBL1000841 | 1.00 | DHFR (0.98) | DHFRFPGSKDM4ETLR4MEN1 | |
| Methotrexate SCHEMBL5307856 | 1.00 | DHFR (0.98) | DHFRFPGSKDM4ETLR4MEN1 | |
| Methotrexate SCHEMBL3712 | 0.99 | DHFR (1.00) | DHFRFPGSKDM4ETLR4MEN1 | |
| Methotrexate SCHEMBL171251 | 0.99 | DHFR (1.00) | DHFRFPGSKDM4ETLR4MEN1 | |
| Methotrexate SCHEMBL2301949 | 0.99 | DHFR (1.00) | DHFRFPGSKDM4ETLR4MEN1 | |
| Methotrexate SCHEMBL16013534 | 0.99 | DHFR (1.00) | DHFRFPGSKDM4ETLR4MEN1 | |
| Methotrexate SCHEMBL20548444 | 0.99 | DHFR (1.00) | DHFRFPGSKDM4ETLR4MEN1 | |
| Methotrexate SCHEMBL3711 | 0.99 | DHFR (1.00) | DHFRFPGSKDM4ETLR4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119564585-A | Silk fibroin microneedle transdermal patch applicable to psoriasis and preparation method thereof | 苏州大学 | 2025-03-07 | — | — | CN | claimed |
| CN-119546336-A | Allo-low immunity bionic nano vesicle for treating cancer | T·马尔科姆 | 2025-02-28 | — | — | CN | claimed |
| CN-112912386-B | Cell penetrating peptides based on influenza virus M2 proteins | 中国医学科学院基础医学研究所 | 2023-10-20 | — | — | CN | claimed |
| CN-115974840-A | Human cereblon ligand and bifunctional compound comprising same | 阿尔维纳斯运营股份有限公司 | 2023-04-18 | — | — | CN | claimed |
| CN-122079960-A | Alkynyl quinazoline compounds | — | 2026-05-26 | — | — | CN | disclosed |
| US-20260091004-A1 | PHARMACEUTICAL INJECTABLE SOLUTION COMPRISING DOPAMINE | INBRAIN PHARMA (FR) | 2026-04-02 | — | — | US | disclosed |
| CN-119564585-B | Silk fibroin microneedle transdermal patch applicable to psoriasis and preparation method thereof | 苏州大学 | 2025-11-07 | — | — | CN | disclosed |
| EP-4586995-A1 | PHARMACEUTICAL INJECTABLE SOLUTION COMPRISING DOPAMINE | InBrain Pharma (FR) | 2025-07-23 | — | — | EP | disclosed |
| CN-109789225-B | DNA monoclonal antibodies targeting checkpoint molecules | 宾夕法尼亚大学理事会 | 2025-05-13 | — | — | CN | disclosed |
| CN-119977993-A | Solid forms of thienopyrimidinedione ACC inhibitors and methods of making the same | 吉利德阿波罗公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-114040760-B | Irreversible inhibitors of MENIN-MLL interactions | 拜欧米富士恩公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-119932188-A | Methods for prostate cancer detection and treatment | 液体活检研究有限责任公司 | 2025-05-06 | — | — | CN | disclosed |
| EP-0145333-B1 | CANDIDA ALBICANS CYTOPLASMIC ANTIGEN, MONOCLONAL ANTIBODIES AGAINST IT AND METHODS FOR THE PREPARATION | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 1991-09-11 | — | — | EP | disclosed |
| WO-1991010506-A1 | AQUEOUS CORE MICROCAPSULES AND METHOD FOR THEIR PREPARATION | TEMPLE UNIVERSITY (US) | 1991-07-25 | — | — | WO | disclosed |
| EP-0433900-A1 | Expression of the recombinant tumor necrosis factor binding protein I (TBP-I) | YEDA RESEARCH AND DEVELOPMENT COMPANY LIMITED (IL) | 1991-06-26 | — | — | EP | disclosed |
| WO-1989008119-A1 | HIGH MOLECULAR WEIGHT PRODRUG DERIVATIVES OF ANTI-INFLAMMATORY DRUGS | SELCH LARSEN CLAUS (DK) | 1989-09-08 | — | — | WO | disclosed |
| US-4806465-A | Cytoplasmic antigens of candida albicans and methods of using the same | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 1989-02-21 | — | — | US | disclosed |
| US-4670382-A | Monoclonal antibody to Candida albicans cytoplasmic antigens and methods of preparing same | Temple University--of the Commonwealth System of Higher Education (US) | 1987-06-02 | — | — | US | disclosed |
| EP-0145333-A2 | Candida albicans cytoplasmic antigen, monoclonal antibodies against it and methods for the preparation | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 1985-06-19 | — | — | EP | disclosed |
| US-4374987-A | FROM 2,4,5,6-TETRAMINOPYRIMIDINE SULFATE, 1,1,3-TRIBROMOACETONE AND A ZINC P-AMINOBENZOYLGLUTAMATE | AMERICAN CYANAMID COMPANY (US) | 1983-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091004-A1 | PHARMACEUTICAL INJECTABLE SOLUTION COMPRISING DOPAMINE | PARK7, SNCA, SLC6A3 | DHFR 3222/4885FPGS 868/4885KDM4E 3224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.